GBS (GBS) Competitors

GBS (NYSE:GBS) and Carmell (NASDAQ:CTCX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Does the media favor GBS or CTCX?

In the previous week, GBS had 1 more articles in the media than Carmell. MarketBeat recorded 1 mentions for GBS and 0 mentions for Carmell. GBS's average media sentiment score of 0.04 beat Carmell's score of 0.00 indicating that GBS is being referred to more favorably in the media.

Company	Overall Sentiment
GBS	Neutral
Carmell	Neutral

Which has higher valuation & earnings, GBS or CTCX?

GBS has higher earnings, but lower revenue than Carmell.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GBS	N/A	N/A	-$8.31M	-$0.56	-2.63
Carmell	$32.84K	1,623.31	-$15.44M	N/A	N/A

Do insiders and institutionals believe in GBS or CTCX?

2.8% of GBS shares are held by institutional investors. Comparatively, 24.2% of Carmell shares are held by institutional investors. 0.3% of GBS shares are held by company insiders. Comparatively, 29.0% of Carmell shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility & risk, GBS or CTCX?

GBS has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Carmell has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Is GBS or CTCX more profitable?

GBS's return on equity of -85.64% beat Carmell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GBS	N/A	-85.64%	-54.42%
Carmell	N/A	-217.50%	-50.22%

Summary

GBS beats Carmell on 5 of the 9 factors compared between the two stocks.